Omeros' OMS721 underwhelms in Phase II

By Jaime De Leon | Oct 2, 2018 | 11:38 PM GMT

Shares of Omeros Corp. (NASDAQ:OMER) regained some ground Tuesday a day after the stock tumbled on data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721 for

Read the full 367 word article

How to gain access

Continue reading with a
two-week free trial.